Pacira Pharmaceuticals (NASDAQ: PCRX) recently received a number of ratings updates from brokerages and research firms:

  • 11/9/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $52.00 price target on the stock.
  • 11/9/2017 – Pacira Pharmaceuticals had its price target lowered by analysts at Jefferies Group LLC to $52.00. They now have a “buy” rating on the stock.
  • 11/9/2017 – Pacira Pharmaceuticals had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 11/9/2017 – Pacira Pharmaceuticals had its price target raised by analysts at Canaccord Genuity from $33.00 to $38.00. They now have a “hold” rating on the stock.
  • 11/8/2017 – Pacira Pharmaceuticals had its price target raised by analysts at BMO Capital Markets from $38.00 to $39.00. They now have a “market perform” rating on the stock.
  • 10/30/2017 – Pacira Pharmaceuticals was downgraded by analysts at Canaccord Genuity from a “buy” rating to a “hold” rating. They now have a $33.00 price target on the stock, down previously from $44.00.
  • 10/27/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $55.00 price target on the stock.
  • 10/26/2017 – Pacira Pharmaceuticals was downgraded by analysts at Janney Montgomery Scott from a “neutral” rating to a “sell” rating. They now have a $27.00 price target on the stock.
  • 10/25/2017 – Pacira Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $87.00 price target on the stock.
  • 10/19/2017 – Pacira Pharmaceuticals had its price target lowered by analysts at Needham & Company LLC from $55.00 to $52.00. They now have a “buy” rating on the stock.
  • 10/13/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $54.00 price target on the stock.
  • 10/9/2017 – Pacira Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Pacira's efforts to expand Exparel's label to boost sales in oral surgery and chronic pain are encouraging. The company also remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. Going forwad, Pacira is looking to expand Exparel's label in the animal health market as well. Shares of the company have outperformed the industry year to date. However, Pacira’s dependence on its key marketed drug, Exparel, for top-line growth is concerning. The company also discontinued the production of DepoCyt(e) due to persistent technical issues specific to DepoCyt.”
  • 10/4/2017 – Pacira Pharmaceuticals had its price target lowered by analysts at Bank of America Corporation from $46.00 to $45.00. They now have a “buy” rating on the stock.
  • 10/3/2017 – Pacira Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $42.00 price target on the stock. According to Zacks, “Pacira's efforts to expand Exparel's label to boost sales in oral surgery and chronic pain are encouraging. The company also remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. Going forwad, Pacira is looking to expand Exparel's label in the animal health market as well. Shares of the company have outperformed the industry year to date. However, Pacira’s dependence on its key marketed drug, Exparel, for top-line growth is concerning. The company also discontinued the production of DepoCyt(e) due to persistent technical issues specific to DepoCyt.”
  • 10/1/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $44.00 price target on the stock, down previously from $48.00.
  • 9/28/2017 – Pacira Pharmaceuticals is now covered by analysts at Goldman Sachs Group, Inc. (The). They set a “neutral” rating and a $41.00 price target on the stock.
  • 9/26/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC.
  • 9/25/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $53.00 price target on the stock.

Shares of Pacira Pharmaceuticals, Inc. (PCRX) traded up $1.90 on Monday, hitting $42.05. 787,300 shares of the stock traded hands, compared to its average volume of 840,020. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99. Pacira Pharmaceuticals, Inc. has a 12 month low of $29.81 and a 12 month high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The firm had revenue of $67.30 million for the quarter, compared to the consensus estimate of $68.99 million. During the same period in the previous year, the firm posted $0.20 earnings per share. The firm’s revenue was down 1.6% on a year-over-year basis. research analysts forecast that Pacira Pharmaceuticals, Inc. will post -0.96 EPS for the current fiscal year.

In related news, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $36.37, for a total transaction of $1,050,547.45. Following the transaction, the chief executive officer now owns 159,164 shares in the company, valued at approximately $5,788,794.68. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Paul J. Hastings sold 1,044 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total transaction of $37,740.60. Following the transaction, the director now owns 3,518 shares in the company, valued at approximately $127,175.70. The disclosure for this sale can be found here. Insiders sold 33,390 shares of company stock valued at $1,215,480 over the last 90 days. 6.60% of the stock is owned by corporate insiders.

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Receive News & Ratings for Pacira Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.